MiR-199a-5p represses the stemness of cutaneous squamous cell carcinoma stem cells by targeting Sirt1 and CD44ICD cleavage signaling

References

• Dotto GP, Rustgi AK. Squamous cell cancers: a unified perspective on biology and genetics. Cancer Cell. 2016;29(5):622–637.
   PubMed Web of Science ®Google Scholar
• Nicolis SK. Cancer stem cells and “stemness” genes in neuro-oncology. Neurobiol Dis. 2007;25(2):217–229.
   PubMed Web of Science ®Google Scholar
• Faber A, Goessler UR, Hoermann K, et al. SDF-1-CXCR4 axis: cell trafficking in the cancer stem cell niche of head and neck squamous cell carcinoma. Oncol Rep. 2013;29(6):2325–2331.
   PubMed Web of Science ®Google Scholar
• Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007;104(3):973–978.
   PubMed Web of Science ®Google Scholar
• Zhao J-S, Li W-J, Ge D, et al. Tumor initiating cells in esophageal squamous cell carcinomas express high levels of CD44. PLoS One. 2011;6(6):e21419.
   PubMed Web of Science ®Google Scholar
• Kajita M, Itoh Y, Chiba T, et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol. 2001;153(5):893–904.
   PubMed Web of Science ®Google Scholar
• Murakami D, Okamoto I, Nagano O, et al. Presenilin-dependent gamma-secretase activity mediates the intramembranous cleavage of CD44. Oncogene. 2003;22(10):1511–1516.
   PubMed Web of Science ®Google Scholar
• Lee JL, Wang MJ, Chen JY. Acetylation and activation of STAT3 mediated by nuclear translocation of CD44. J Cell Biol. 2009;185(6):949–957.
   PubMed Web of Science ®Google Scholar
• Screaton GR, Bell MV, Jackson DG, et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci U S A. 1992;89(24):12160–12164.
   PubMed Web of Science ®Google Scholar
• Ponta H, Herrlich P. The CD44 protein family: roles in embryogenesis and tumor progression. Front Biosci. 1998;3:d650–656.
   PubMedGoogle Scholar
• Herold-Mende C, Seiter S, Born AI, et al. Expression of CD44 splice variants in squamous epithelia and squamous cell carcinomas of the head and neck. J Pathol. 1996;179(1):66–73.
   PubMed Web of Science ®Google Scholar
• Thorne RF, Legg JW, Isacke CM. The role of the CD44 transmembrane and cytoplasmic domains in co-ordinating adhesive and signalling events. J Cell Sci. 2004;117(Pt(3)):373–380.
   Web of Science ®Google Scholar
• Senbanjo LT, Chellaiah MA. CD44: A multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells. Front Cell Dev Biol. 2017;5:18.
   PubMed Web of Science ®Google Scholar
• Okamoto I, Kawano Y, Murakami D, et al. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J Cell Biol. 2001;155(5):755–762.
   PubMed Web of Science ®Google Scholar
• Yanaihara N, Caplen N, Bowman E, et al. Unique MicroRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9(3):189–198.
   PubMed Web of Science ®Google Scholar
• Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med. 2009;60:167–179.
   PubMed Web of Science ®Google Scholar
• O’Donnell KA, Wentzel EA, Zeller KI, et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005;435(7043):839–843.
   PubMed Web of Science ®Google Scholar
• Jiang J, Gusev Y, Aderca I, et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res. 2008;14(2):419–427.
   PubMed Web of Science ®Google Scholar
• Wang S-H, Zhou J-D, He Q-Y, et al. MiR-199a inhibits the ability of proliferation and migration by regulating CD44-Ezrin signaling in cutaneous squamous cell carcinoma cells. Int J Clin Exp Pathol. 2014;7(10):7131–7141.
   PubMed Web of Science ®Google Scholar
• Shin AN, Han L, Dasgupta C, et al. SIRT1 increases cardiomyocyte binucleation in the heart development. Oncotarget. 2018;9(8):7996–8010.
   PubMedGoogle Scholar
• Lammich S, Okochi M, Takeda M, et al. Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the Secretion of an Aβ-like peptide. J Biol Chem. 2002;277(47):44754–44759.
   PubMed Web of Science ®Google Scholar
• Jiang LY, Zhang XL, Du P, et al. gamma-secretase inhibitor, dapt inhibits self-renewal and stemness maintenance of ovarian cancer stem-like cells in vitro. Chin J Cancer Res. 2011;23(2):140–146.
   PubMed Web of Science ®Google Scholar
• Li LC, Wang DL, Wu YZ, et al. Gastric tumor-initiating CD44(+) cells and epithelial-mesenchymal transition are inhibited by gamma-secretase inhibitor DAPT. Oncol Lett. 2015;10(5):3293–3299.
   PubMed Web of Science ®Google Scholar
• Yu J, Auwerx J. Protein deacetylation by SIRT1: an emerging key post-translational modification in metabolic regulation. Pharmacol Res. 2010;62(1):35–41.
   PubMed Web of Science ®Google Scholar
• Bradbury CA, Khanim FL, Hayden R, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia. 2005;19(10):1751–1759.
   PubMed Web of Science ®Google Scholar
• Huffman DM, Grizzle WE, Bamman MM, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 2007;67(14):6612–6618.
   PubMed Web of Science ®Google Scholar
• Stunkel W, Peh BK, Tan YC, et al. Function of the SIRT1 protein deacetylase in cancer. Biotechnol J. 2007;2(11):1360–1368.
   PubMedGoogle Scholar
• Hida Y, Kubo Y, Murao K, et al. Strong expression of a longevity-related protein, SIRT1, in Bowen’s disease. Arch Dermatol Res. 2007;299(2):103–106.
   PubMed Web of Science ®Google Scholar
• Rane S, He M, Sayed D, et al. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res. 2009;104(7):879–886.
   PubMed Web of Science ®Google Scholar
• Facompre N, Nakagawa H, Herlyn M, et al. Stem-like cells and therapy resistance in squamous cell carcinomas. Adv Pharmacol. 2012;65:235–265.
   PubMedGoogle Scholar
• Cho Y, Lee H-W, Kang H-G, et al. Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancer. Oncotarget. 2015;6(11):8709–8721.
   PubMedGoogle Scholar
• Matsuoka J, Yashiro M, Sakurai K, et al. Role of the stemness factors sox2, oct3/4, and nanog in gastric carcinoma. J Surg Res. 2012;174(1):130–135.
   PubMed Web of Science ®Google Scholar
• Gwak JM, Kim M, Kim HJ, et al. Expression of embryonal stem cell transcription factors in breast cancer: oct4 as an indicator for poor clinical outcome and tamoxifen resistance. Oncotarget. 2017;8(22):36305–36318.
   PubMedGoogle Scholar
• Habu N, Imanishi Y, Kameyama K, et al. Expression of Oct3/4 and Nanog in the head and neck squamous carcinoma cells and its clinical implications for delayed neck metastasis in stage I/II oral tongue squamous cell carcinoma. BMC Cancer. 2015;15:730.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhao K, Hackert T, et al. CD44/CD44v6 a reliable companion in cancer-initiating cell maintenance and tumor progression. Front Cell Dev Biol. 2018;6:97.
   PubMed Web of Science ®Google Scholar
• Cui W, Ke JZ, Zhang Q, et al. The intracellular domain of CD44 promotes the fusion of macrophages. Blood. 2006;107(2):796–805.
   PubMed Web of Science ®Google Scholar
• Wang S, CAO KE, He Q, et al. miR-199a-5p induces cell invasion by suppressing E-cadherin expression in cutaneous squamous cell carcinoma. Oncol Lett. 2016;12(1):97–101.
   PubMed Web of Science ®Google Scholar
• Liu R, Liu C, Zhang D, et al. miR-199a-3p targets stemness-related and mitogenic signaling pathways to suppress the expansion and tumorigenic capabilities of prostate cancer stem cells. Oncotarget. 2016;7(35):56628–56642.
   PubMedGoogle Scholar
• Henry JC, Park J-K, Jiang J, et al. miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun. 2010;403(1):120–125.
   PubMed Web of Science ®Google Scholar
• Yamakuchi M. MicroRNA regulation of SIRT1. Front Physiol. 2012;3:68.
   PubMed Web of Science ®Google Scholar
• Deng CX. SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci. 2009;5(2):147–152.
   PubMed Web of Science ®Google Scholar